Cart summary

You have no items in your shopping cart.

Navicixizumab

Navicixizumab

Catalog Number: orb1980573

DispatchUsually dispatched within 5-10 working days
Contact us for a quotation
Catalog Numberorb1980573
CategoryAntibodies
DescriptionNavicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3].
CAS Number1638338-43-8
Purity98.00%
ConjugationUnconjugated
TargetNavicixizumab
Biological ActivityNavicixizumab (OMP-305B83) is a bispecific anti- VEGF and anti- DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3] .
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
NoteFor research use only
Expiration Date12 months from date of receipt.
  • Anti-DLL4 Reference Antibody (navicixizumab) [orb1806225]

    ELISA,  FA,  FACS,  Kinetics

    Human

    Monoclonal

    Unconjugated

    50 μg, 100 μg, 1 mg, 5 mg
  • Anti-DLL4 Reference Antibody (navicixizumab) [orb1818447]

    ELISA,  FC

    Human, Monkey

    Monoclonal

    Unconjugated

    100 μg
  • Navicixizumab (DLL4/VEGFA) - Research Grade Biosimilar [orb1237511]

    Recombinant

    Unconjugated

    0.1 mg
  • Navicixizumab [orb1140914]

    Unconjugated

    5 mg, 1 mg
  • Navicixizumab [orb2703343]

    Unconjugated

    100 mg